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PDiscussion
Dr Todd K. Rosengart (Stony Brook, NY). The authors are to be
congratulated for translating solid experimental laboratory data
into a logical extension in clinical Unfortunately, as has been the
case on a number of occasions, the human condition has confounded
the efforts to reasonably and logically test some of your experimen-
tal hypotheses. I have a number of questions; but I’ll ask you 4,
which I’ll ask you one at a time for simplicity.
First, why did you not administer VEGF into an unrevascular-
ized territory so you could take advantage of a low baseline perfu-
sion level as opposed to administering VEGF into the LAD
territory? Obviously, this creates potential problems of artifact
because of your bypass grafts.
Dr Ruel. This is an excellent question and a point that we had to
resolve at the design level of the study. VEGF is a relatively poor
angiogenic factor, but it is intimately NO dependent, perhaps
more than fibroblast growth factor-2 and hepatocyte growth factor,
which are other cytokines that are potentially more robust. We also
chose VEGF first because it has been widely studied in humans, and
part of this comes from your work as well. We also chose VEGF
because it was available from our collaborators in addition to being
NO dependent.
On the other hand, we did not want to expose patients to the pos-
sibility of ineffective angiogenesis, which could have happened in
the VEGF and placebo groups. We thus protected our patients by
bypassing all their territories as well as we could, considering that
those patients all had diffuse LAD disease.
Furthermore, we had a precise measure of myocardial blood
flow. By performing the anterior myocardial bypass at the same tar-
get site in every patient, which was the distal LAD, we could focus
on the basal, mid, and early distal portions of the anterior wall to iso-
late the effect of VEGF.The Journal of ThorIn addition, the performance of baseline PET scanning, which
would be repeated at 3 months, early after the operation instead of
before the operation, accounted as best as possible for the confound-
ing effects of CABG.
Dr Rosengart. You mentioned in your article and presentation
that you used intraoperative validation or verification that the
LAD was suitable for your experimental protocol. Can you go
into a little bit more detail on that? Or conversely, did you attempt
to use any kind of strict angiographic guidelines to determine
whether you’d have a consistent cohort to study?
Dr Ruel. Those patients were screened on the basis of their
potential ungraftability. Several of them came from other centers
and were referred to us as ungraftable or likely ungraftable.
The intraoperative validation was informal. Initially, the patients
were screened and found to have a diffusely diseased LAD; in many
cases we thought that a LAD graft would perhaps not be construct-
ible. As many of us know, if you really put your mind to it, you can
basically graft anything with a lumen in it. So this is what we did,
and we bypassed the initial healthy portion of the LAD, which in
all patients corresponded to its most distal portion.
The intraoperative validation was done by a non-investigator car-
diac surgeon who confirmed that each patient had diffuse distal dis-
ease, but there were no specific radiologic measures to determine
eligibility for the trial. As you know, measures of coronary disease
diffuseness are controversial, and despite attempts in the literature
to develop those, they remain neither well accepted nor used.
DrRosengart. Again, in the same regard, you used baseline per-
fusion assay at days 3 to 5, or even in one case, I guess, day 7 post-
operatively. I’d be concerned that this introduced some variability.
Although you clearly show a difference between the experimental
and control groups, how do you know that the change in perfusion
is completely a VEGF effect as opposed to some collateralization
occurring because of the bypass?
Dr Ruel. You’re absolutely right. Again, your point deals with
the issues of doing this study in humans. We had few alternatives.
We thought that doing the baseline PET scanning preoperatively
would be less precise than doing what we did. However, there are
patients for whom undergoing a full PET scan 3 days after a bypass
operation is not ideal, especially those, as in this population, who
have diffuse coronary disease and may consequently have had
a slightly longer operation.
You’re absolutely right that VEGF has several effects. Angio-
genic cytokines are not only angiogenic but also have acute vascular
and other effects. For instance, VEGF results in local vasodilatation
and increased permeability. We did see some of these effects on
baseline PET scanning and tried to objectively and anatomically
account for them as best as possible.
As you know, the onset of action of VEGF and other angiogenic
cytokines is usually approximately 2 weeks, so we considered that
the first 5 days were relatively protected from most of the angiogenic
effects of the protein. It is possible that some patients may have been
better responders and their effects started before.
DrRosengart.Can you tell us a little bitmore about the toxicity, or
the purported toxicity, of L-arginine? Is this a real phenomenon or how
do we deal with that? If it is real, are there alternatives (which obviously
is NO or nitroglycerin) that would be suitable in a clinical arena?
Dr Ruel. I think a lot of researchers are disappointed by the bad
press recently attributed to L-arginine because of a single relativelyacic and Cardiovascular Surgery c Volume 135, Number 4 769
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CSPlimited scope trial published about a year ago. The trial dealt with
patients who had an acute ST elevation, had no revascularization,
and were randomized to receive L-arginine or not.
There may be other ways to modify endothelial function and NO
bioavailability. One way, for instance, may be to up-regulateNotice of Correction
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